Griseofulvin teratology

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We investigated maternal griseofulvin exposure in pregnancies ending with conjoined twins. Of more than 100,000 congenital anomaly cases in the Hungarian Congenital Malformation Registry 1970-86, 39 were conjoined twins. The birth prevalence of conjoined twin sets is 1 in about 60,000 in Hungary. Griseofulvin was marketed in Hungary in 1970 with the warning 'no use during pregnancy'. Data on maternal drug ingestion during pregnancy are available for all the conjoined twins but griseofulvin exposure was not mentioned for any of them. In our case-control surveillance system in 1980-84 there were 6786 congenital anomaly cases and 10,962 matched controls. Griseofulvin use during pregnancy was very rare. 3 griseofulvin exposures occurred between the sixth and ninth months of pregnancy in the matched controls and 2 in congenital anomaly cases (heart defect after exposure in months two and three, and pyloric stenosis after exposure in the first month).

Original languageEnglish
Pages (from-to)1042
Number of pages1
JournalThe Lancet
Volume1
Issue number8540
Publication statusPublished - 1987

Fingerprint

Teratology
Griseofulvin
Conjoined Twins
Pregnancy
Hungary
Pyloric Stenosis
Maternal Exposure
Registries
Eating
Mothers
Parturition
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Griseofulvin teratology. / Métneki, J.; Czeizel, E.

In: The Lancet, Vol. 1, No. 8540, 1987, p. 1042.

Research output: Contribution to journalArticle

Métneki, J & Czeizel, E 1987, 'Griseofulvin teratology', The Lancet, vol. 1, no. 8540, pp. 1042.
Métneki, J. ; Czeizel, E. / Griseofulvin teratology. In: The Lancet. 1987 ; Vol. 1, No. 8540. pp. 1042.
@article{092741d46fb440fc9babcae93cca126a,
title = "Griseofulvin teratology",
abstract = "We investigated maternal griseofulvin exposure in pregnancies ending with conjoined twins. Of more than 100,000 congenital anomaly cases in the Hungarian Congenital Malformation Registry 1970-86, 39 were conjoined twins. The birth prevalence of conjoined twin sets is 1 in about 60,000 in Hungary. Griseofulvin was marketed in Hungary in 1970 with the warning 'no use during pregnancy'. Data on maternal drug ingestion during pregnancy are available for all the conjoined twins but griseofulvin exposure was not mentioned for any of them. In our case-control surveillance system in 1980-84 there were 6786 congenital anomaly cases and 10,962 matched controls. Griseofulvin use during pregnancy was very rare. 3 griseofulvin exposures occurred between the sixth and ninth months of pregnancy in the matched controls and 2 in congenital anomaly cases (heart defect after exposure in months two and three, and pyloric stenosis after exposure in the first month).",
author = "J. M{\'e}tneki and E. Czeizel",
year = "1987",
language = "English",
volume = "1",
pages = "1042",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8540",

}

TY - JOUR

T1 - Griseofulvin teratology

AU - Métneki, J.

AU - Czeizel, E.

PY - 1987

Y1 - 1987

N2 - We investigated maternal griseofulvin exposure in pregnancies ending with conjoined twins. Of more than 100,000 congenital anomaly cases in the Hungarian Congenital Malformation Registry 1970-86, 39 were conjoined twins. The birth prevalence of conjoined twin sets is 1 in about 60,000 in Hungary. Griseofulvin was marketed in Hungary in 1970 with the warning 'no use during pregnancy'. Data on maternal drug ingestion during pregnancy are available for all the conjoined twins but griseofulvin exposure was not mentioned for any of them. In our case-control surveillance system in 1980-84 there were 6786 congenital anomaly cases and 10,962 matched controls. Griseofulvin use during pregnancy was very rare. 3 griseofulvin exposures occurred between the sixth and ninth months of pregnancy in the matched controls and 2 in congenital anomaly cases (heart defect after exposure in months two and three, and pyloric stenosis after exposure in the first month).

AB - We investigated maternal griseofulvin exposure in pregnancies ending with conjoined twins. Of more than 100,000 congenital anomaly cases in the Hungarian Congenital Malformation Registry 1970-86, 39 were conjoined twins. The birth prevalence of conjoined twin sets is 1 in about 60,000 in Hungary. Griseofulvin was marketed in Hungary in 1970 with the warning 'no use during pregnancy'. Data on maternal drug ingestion during pregnancy are available for all the conjoined twins but griseofulvin exposure was not mentioned for any of them. In our case-control surveillance system in 1980-84 there were 6786 congenital anomaly cases and 10,962 matched controls. Griseofulvin use during pregnancy was very rare. 3 griseofulvin exposures occurred between the sixth and ninth months of pregnancy in the matched controls and 2 in congenital anomaly cases (heart defect after exposure in months two and three, and pyloric stenosis after exposure in the first month).

UR - http://www.scopus.com/inward/record.url?scp=0023113818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023113818&partnerID=8YFLogxK

M3 - Article

C2 - 2883385

AN - SCOPUS:0023113818

VL - 1

SP - 1042

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8540

ER -